Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

Peter Richmond; H.S. Marshall; M.D. Nissen; Q. Jiang; K.U. Jansen; M. Garcés-Sánchez; F. Martinón-Torres; J. Beeslaar; L. Szenborn; J. Wysocki; J. Eiden; S.L. Harris; T.R. Jones; J.L. Perez

doi:10.1016/S1473-3099(12)70087-7

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

Peter Richmond, H.S. Marshall, M.D. Nissen, Q. Jiang, K.U. Jansen, M. Garcés-Sánchez, F. Martinón-Torres, J. Beeslaar, L. Szenborn, J. Wysocki, J. Eiden, S.L. Harris, T.R. Jones, J.L. Perez

Research output: Contribution to journal › Article

107 Citations (Scopus)

Original language	English
Pages (from-to)	597-607
Journal	The Lancet Infectious Diseases
Volume	12
Issue number	8
DOIs	https://doi.org/10.1016/S1473-3099(12)70087-7
Publication status	Published - 2012

Access to Document

10.1016/S1473-3099(12)70087-7

Cite this

Richmond, P., Marshall, H. S., Nissen, M. D., Jiang, Q., Jansen, K. U., Garcés-Sánchez, M., Martinón-Torres, F., Beeslaar, J., Szenborn, L., Wysocki, J., Eiden, J., Harris, S. L., Jones, T. R., & Perez, J. L. (2012). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 12(8), 597-607. https://doi.org/10.1016/S1473-3099(12)70087-7

Richmond, Peter ; Marshall, H.S. ; Nissen, M.D. ; Jiang, Q. ; Jansen, K.U. ; Garcés-Sánchez, M. ; Martinón-Torres, F. ; Beeslaar, J. ; Szenborn, L. ; Wysocki, J. ; Eiden, J. ; Harris, S.L. ; Jones, T.R. ; Perez, J.L. / Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. In: The Lancet Infectious Diseases. 2012 ; Vol. 12, No. 8. pp. 597-607.

@article{d42a2bade5c140228b3634452c63562b,

title = "Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial",

author = "Peter Richmond and H.S. Marshall and M.D. Nissen and Q. Jiang and K.U. Jansen and M. Garc{\'e}s-S{\'a}nchez and F. Martin{\'o}n-Torres and J. Beeslaar and L. Szenborn and J. Wysocki and J. Eiden and S.L. Harris and T.R. Jones and J.L. Perez",

year = "2012",

doi = "10.1016/S1473-3099(12)70087-7",

language = "English",

volume = "12",

pages = "597--607",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier",

number = "8",

}

Richmond, P, Marshall, HS, Nissen, MD, Jiang, Q, Jansen, KU, Garcés-Sánchez, M, Martinón-Torres, F, Beeslaar, J, Szenborn, L, Wysocki, J, Eiden, J, Harris, SL, Jones, TR & Perez, JL 2012, 'Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial', The Lancet Infectious Diseases, vol. 12, no. 8, pp. 597-607. https://doi.org/10.1016/S1473-3099(12)70087-7

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. / Richmond, Peter; Marshall, H.S.; Nissen, M.D.; Jiang, Q.; Jansen, K.U.; Garcés-Sánchez, M.; Martinón-Torres, F.; Beeslaar, J.; Szenborn, L.; Wysocki, J.; Eiden, J.; Harris, S.L.; Jones, T.R.; Perez, J.L.

In: The Lancet Infectious Diseases, Vol. 12, No. 8, 2012, p. 597-607.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

AU - Richmond, Peter

AU - Marshall, H.S.

AU - Nissen, M.D.

AU - Jiang, Q.

AU - Jansen, K.U.

AU - Garcés-Sánchez, M.

AU - Martinón-Torres, F.

AU - Beeslaar, J.

AU - Szenborn, L.

AU - Wysocki, J.

AU - Eiden, J.

AU - Harris, S.L.

AU - Jones, T.R.

AU - Perez, J.L.

PY - 2012

Y1 - 2012

U2 - 10.1016/S1473-3099(12)70087-7

DO - 10.1016/S1473-3099(12)70087-7

M3 - Article

VL - 12

SP - 597

EP - 607

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 8

ER -

Richmond P, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2012;12(8):597-607. https://doi.org/10.1016/S1473-3099(12)70087-7